Justice Ministry prepared to re-open Kosovo teen’s asylum application

The Justice Ministry is prepared to re-open the case of deported Kosovan asylum seeker Remzi Baftijari after it was revealed that the anti-depressive medicine the 15-year-old was prescribed in Denmark is unavailable in Kosovo.

Baftijari, who had lived in a Danish asylum camp since he was three, was deported two months ago after a request to be permitted to stay based on his psychological condition was rejected on the grounds that he could obtain the medication in Kosovo.

An investigation later revealed that the medication is not available legally there. 

DR Nyheder 

SEE RELATED: Woman who testified against her human traffickers risks deportation

Interested in receiving stories like these delivered to your inbox by 8am each weekday? Sign up for the Morning Briefing or any of our other newsletters today.





  • How internationals can benefit from joining trade unions

    How internationals can benefit from joining trade unions

    Being part of a trade union is a long-established norm for Danes. But many internationals do not join unions – instead enduring workers’ rights violations. Find out how joining a union could benefit you, and how to go about it.

  • Internationals in Denmark rarely join a trade union

    Internationals in Denmark rarely join a trade union

    Internationals are overrepresented in the lowest-paid fields of agriculture, transport, cleaning, hotels and restaurants, and construction – industries that classically lack collective agreements. A new analysis from the Workers’ Union’s Business Council suggests that internationals rarely join trade unions – but if they did, it would generate better industry standards.

  • Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    The numbers are especially striking amongst the 3,477 business and economics students polled, of whom 31 percent elected Novo Nordisk as their favorite, compared with 20 percent last year.